Advertisement

Sex Roles

, Volume 54, Issue 5–6, pp 401–411 | Cite as

Fallout from the Women’s Health Study: A Short-lived Vindication for Feminists and the Resurrection of Hormone Therapies

  • Ann M. VodaEmail author
  • Carol A. Ashton
Original Article

Abstract

The Women’s Health Initiative studies were begun in 1997, in large part the result of women’s health activists who for 40 years questioned the safety of hormone use at menopause and criticized the menopause as disease ideology. The studies were prematurely discontinued when investigators found that heretofore acclaimed benefits of hormone use were not supported. Risks to health such as stroke, breast cancer, and thrombophlebitis were found. A feeling of vindication was experienced by feminists but was quickly replaced by cautious optimism as strategies to continue hormone use were published and quality of life issues tied to symptom management emerged. The focus of this article is a review of the hormone story, a discussion of the implications of the Women’s Health Initiative results, and strategies for resolution of the continuing hormone dilemma.

Keywords

Menopause Women’s health initiative Hormone replacement 

References

  1. Allina, A., & Fugh-Berman, A. (2003, January–February). Natural hormones: Are they a safe alternative? A Friend Indeed, 19(6), 6–7.Google Scholar
  2. Baker, N. (2003, June 26). Wyeth drops on news about drug. Wall Street Journal, C3.Google Scholar
  3. Bellino, F. (2002). Menopause and the NIH Part I: Research needs and funding mechanisms. Menopause Management, 11(1), 13–21.Google Scholar
  4. Center for Disease Control Reproductive Health Information Source. (2003). Women’s reproductive health, hysterectomy. Retrieved May 13, 2003, at http://www.cdc.gov/reproductivehealth_hysterec.htm.
  5. Chrisler, J. C., Torrey, J. W., & Matthes, M. M. (1991). Brittle bones and sagging breasts, loss of femininity and loss of sanity: The media describe the Menopause. In A. M. Voda & R. Conover (Eds.), Proceedings of the 8th Conference, Society for Menstrual Cycle Research (pp. 23–35). Salt Lake City: Society for Menstrual Cycle Research.Google Scholar
  6. Coney, S. (1994). The menopause industry: How the medical establishment exploits women. Alameda, CA: Hunter House.Google Scholar
  7. Cowley, G., & Springen, K. (2002, July 22). The end of the age of estrogen. Newsweek, 140(4), 38–41.Google Scholar
  8. Dan, A. J., Graham, E. A., & Beecher, C. P. (1980). The menstrual cycle. Vol. I: A synthesis of interdisciplinary research. New York: Springer.Google Scholar
  9. Food and Drug Administration (2003, March 13). FDA approves lower dose of prempro, a combination of estrogen and progestin drug for postmenopausal women. FDA News, 3–16.Google Scholar
  10. Grossman, M., & Bart, P. (1980). The politics of menopause. In A. J. Dan, E. A. Graham, & C. P. Beecher (Eds.), The menstrual cycle: A synthesis of interdisciplinary research (Vol. I, pp. 179–185). New York: Springer.Google Scholar
  11. Keenan, N. L., Mark, S., Fugh-Berman, A., Browne, D., Kaczmarczyk, J., & Hunter, C. (2003). Severity of menopausal symptoms and use of both conventional and complementary/alternative therapies. Menopause, 10, 507–515.PubMedCrossRefGoogle Scholar
  12. MacPherson, K. I. (1981). Menopause as disease: The social construction of a metaphor. Advances in Nursing Science, 3, 95–113.PubMedGoogle Scholar
  13. Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., et al. (2003). Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine, 349, 523–534.PubMedCrossRefGoogle Scholar
  14. National Women’s Health Network (2002). The truth about hormone replacement therapy: How to break free from the medical myths of menopause. Washington, DC: National Women’s Health Network.Google Scholar
  15. National Women’s Health Report. (2004, April). Managing menopause: Hormone therapy and other options. National Women’s Health Resource Center, 26(2), 2–6.Google Scholar
  16. North American Menopause Society (2003). Estrogen and progestogen use in peri- and postmenopausal women: September 2003 position statement of The North American Menopause Society. Menopause, 10, 497–506.Google Scholar
  17. Northup, C. (2001). The wisdom of menopause: Creating physical and emotional health and healing during the change. New York: Bantam.Google Scholar
  18. Ockene, J. K., Barad, D. H., Cochrane, B. B., Larson, J. C., Gass, M., Wassertheil-Smoller, et al. (2005). Symptom experience after discontinuing use of estrogen plus progestin. Journal of the American Medical Society, 294, 183–193.Google Scholar
  19. Ontario Women’s Health Council (2002, March–April). Too many women getting hysterectomies when less invasive methods exist. A Friend Indeed, 2.Google Scholar
  20. Perlmutter, E., & Bart, P. B. (1982). Changing views of “the change”: A critical review and suggestions for an attributional approach. In A. M. Voda, M. Dinnerstein, & S. R. O’Donnell (Eds.), Changing perspectives on menopause (pp. 187–199). Austin, TX: University of Texas Press.Google Scholar
  21. Quindlen, A. (2002, July 29). And now for a hot flash. Newsweek, 64.Google Scholar
  22. Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., & Stefanick, M. L. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. Journal of the American Medical Society, 288, 321–333.Google Scholar
  23. Rubin, R. (2002, October 29). A body of hormone research. USA Today, D10.Google Scholar
  24. Santee, C. (2004, March 5). Pair saves horses from slaughter. Idaho State Journal, 1.Google Scholar
  25. Seaman, B., & Seaman, G. (1977). Women and the crisis in sex hormones. New York: Rawson.Google Scholar
  26. Smith, D. C., Prentice, R., Thompson, D. J., & Herrmann, W. L. (1975). Association of exogenous estrogen and endometrial carcinoma. New England Journal of Medicine, 293, 1164–1167.PubMedCrossRefGoogle Scholar
  27. Specter, M. (2004, February 2). Miracle in a bottle. The New Yorker, 64–75.Google Scholar
  28. The Women’s Health Initiative Sterring Committee (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The woman’s health initiative randomized controlled trial. Journal of the American Medical Association, 291, 1701–1712.CrossRefGoogle Scholar
  29. Utian, W. (2003). Apples are not oranges: Prevention and treatment are different. Menopause Management, 12(4), 7–8.Google Scholar
  30. Utian, W. (2004). Women’s health initiative, Round 2: Is this the opportunity to clear the air on postmenopausal hormone use? Menopause Management, 13(4), 8–10.Google Scholar
  31. Utian, W. (2005). The true symptoms associated with menopause confirmed after 33 years: Better late than never, but let’s move on now! Menopause Management, 14(4), 7–8.Google Scholar
  32. Voda, A. M. (1996, September). Menopause preparedness: Stabilizing the line of fault. Paper presented at the meeting of the North American Menopause Society, Chicago.Google Scholar
  33. Voda, A. M. (1997). Menopause me and you: The sound of women pausing. New York: Haworth Press.Google Scholar
  34. Voda, A. M., Dinnerstein, M., & O’Donnell, S. (1982). Changing perspectives on menopause. Austin, TX: University of Texas Press.Google Scholar
  35. Warren, M. (2002). The need for proper diagnosis and treatment of menorrhagia. Menopause Management, 11(6), 10–15.Google Scholar
  36. Wilson, R. (1966). Feminine forever. New York: M. Evans Co.Google Scholar
  37. Women’s Health Initiative Study Group. (1998). Design of the women’s health initiative clinical trial and observational study. Controlled Clinical Trials, 19, 61–109.Google Scholar
  38. Ziel, H. K., & Finkle, W. D. (1975). Increased risk of endometrial carcinoma among users of conjugated estrogens. New England Journal of Medicine, 293, 1168–1170.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Professor Emerita, College of NursingUniversity of UtahSalt Lake CityUSA
  2. 2.Associate Dean and Director, School of NursingIdaho State UniversityPocatelloUSA

Personalised recommendations